|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
价值评估 |
盈利(现时/预测)
-45.43/-3.90
|
企业价值
1.52B
|
资产负债 |
每股账面净值
-0.81
|
现金流量 |
现金流量率
--
|
损益表 |
收益
886.00K
|
每股收益
0.30
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟:2024/05/18 06:17 EDT
同行比较之报价最少15分钟延迟
业务概览
|
|||
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. A range of pharmaceutical options to address IBD exists, including anti-inflammatory drugs, immunosuppressants, and biologics. |